Drug: CB-5945: chronic pain clinical trials
Registry records that list "Drug: CB-5945" as an intervention. Being studied does not mean an intervention works or is approved.
0
Trials with Canadian sites
0
Recruiting in Canada
4
Registry records in total
Trials in Canada
No trial with a Canadian site lists this intervention in this snapshot.
Trials worldwide (outside Canada)
4 trials, 0 recruiting or not yet recruiting. Recruiting first.
| Phase | Countries | ||||
|---|---|---|---|---|---|
| The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01901341 | Terminated | Phase 3 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-07-02 | |
| Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01901302 | Terminated | Phase 3 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-05-20 | |
| Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01901328 | Terminated | Phase 3 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-04-07 | |
| Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01696643 | Terminated | Phase 3 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-10-12 |
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status.